专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JP2007326877A Therapeutic composition containing glutathione analog 审中-公开
标题翻译：含有GLUTATHIONE模拟物的治疗组合物
公开(公告)号：JP2007326877A
公开(公告)日：2007-12-20
申请号：JP2007229798
申请日：2007-09-05
申请人： Telik Inc , テリック,インコーポレイテッド
发明人： REDELMEIER THOMAS , KAUVAR LAWRENCE M , LUM ROBERT T , LYTTLE MATTHEW H , MACSATA ROBERT W , SCHOW STEVEN R , VILLAR HUGO O , KOZLOWSKI MICHAEL R
IPC分类号： A61K38/00 , A61K9/107 , A61K9/127 , A61K38/06 , A61P7/00 , A61P7/06 , A61P35/00 , A61P35/02 , A61P43/00 , C07K5/037 , C07K5/093
CPC分类号： A61K9/127 , A61K9/1075 , A61K38/063
摘要： PROBLEM TO BE SOLVED: To provide a pharmaceutical composition and a method for using the composition. SOLUTION: The invention provides a lipid preparation of a glutathione analog and a method for the production of the preparation. The preparation is used for stimulating hematopoiesis, protecting hematopoietic cells from damage caused by radiation or chemotherapy, or potentiating the stimulatory action of one or a combination of cytokines on colony formation by hematopoietic progenitor cells, protecting a patient from a destructive effect of a chemotherapeutic agent or irradiation, or potentiating the effect of a chemotherapeutic agent. COPYRIGHT: (C)2008,JPO&INPIT
摘要翻译：待解决的问题：提供一种药物组合物和使用该组合物的方法。解决方案：本发明提供了一种谷胱甘肽类似物的制剂及其制备方法。该制剂用于刺激造血细胞，保护造血细胞免受辐射或化疗引起的损伤，或增强细胞因子的一种或组合对造血祖细胞的集落形成的刺激作用，保护患者免受化学治疗剂的破坏作用或照射，或增强化学治疗剂的作用。版权所有（C）2008，JPO＆INPIT

2. 发明申请

WO0230514A3 INSULIN RECEPTOR ACTIVATORS FOR THE TREATMENT OF METABOLIC DISORDERS IN HUMANS RESULTING FROM TREATMENT OF HIV INFECTION WITH HIV PROTEASE INHIBITORS 审中-公开
标题翻译：胰岛素受体激活剂治疗艾滋病病毒感染艾滋病病毒感染艾滋病毒抑制剂治疗人类代谢障碍
公开(公告)号：WO0230514A3
公开(公告)日：2003-07-31
申请号：PCT/US0142733
申请日：2001-10-10
申请人： TELIK INC , MANCHEM PRASAD V V S V , LUM ROBERT T , SCHOW STEVEN R
发明人： MANCHEM PRASAD V V S V , LUM ROBERT T , SCHOW STEVEN R
IPC分类号： A61K45/00 , A61K31/17 , A61K31/18 , A61K31/185 , A61K31/19 , A61K31/195 , A61K31/655 , A61P3/00 , A61P3/06 , A61P3/10 , A61P5/50 , A61P43/00 , C07C309/51 , C07C311/47
CPC分类号： A61K31/19 , A61K31/17 , A61K31/18 , A61K31/185 , A61K31/195 , A61K31/655
摘要： The present invention comprises the use of insulin receptor activating compounds, optionally in conjunction with insulin, for the treatment of HIV protease inhibitor-induced metabolic disorders. Any insulin receptor activating compounds is suitable for the practice of the invention. In addition, preferred compounds are disclosed. Methods of treating a person suffering from HIV protease inhibitor-induced metabolic disorders such as lipodystrophy, hypertriglyceridemia, insulin resistance, hyperglycemia, diabetes and ketoacidosis are also provided.
摘要翻译：本发明包括使用任选与胰岛素结合的胰岛素受体活化化合物用于治疗HIV蛋白酶抑制剂诱导的代谢紊乱。任何胰岛素受体活化化合物适用于本发明的实践。此外，公开了优选的化合物。还提供了治疗患有HIV蛋白酶抑制剂诱导的代谢紊乱如脂肪营养不良，高甘油三酯血症，胰岛素抵抗，高血糖，糖尿病和酮症酸中毒的人的方法。

3. 发明申请

WO0044366A2 THERAPEUTIC COMPOSITIONS CONTAINING GLUTATHIONE ANALOGS 审中-公开
标题翻译：含有GLUTATHIONE类似物的治疗组合物
公开(公告)号：WO0044366A2
公开(公告)日：2000-08-03
申请号：PCT/US0002297
申请日：2000-01-27
申请人： TELIK INC
发明人： REDELMEIER THOMAS , KAUVAR LAWRENCE M , LUM ROBERT T , LYTTLE MATTHEW H , MACSATA ROBERT W , SCHOW STEVEN R , VILLAR HUGO O , KOZLOWSKI MICHAEL R
IPC分类号： A61K9/107 , A61K9/127 , A61K38/00 , A61K38/06 , A61P7/00 , A61P7/06 , C07K5/093 , A61K31/00
CPC分类号： A61K9/127 , A61K9/1075 , A61K38/063
摘要： Pharmaceutical compositions and methods of using them. Lipid formulations of a glutathione analog and methods of manufacturing them. Their use to stimulate hematopoiesis, protect hematopoietic cells from damage caused by radiation or chemotherapy, or potentiate the stimulatory action of one or a combination of cytokines on colony formation by hematopoietic progenitor cells, protect a subject from a destructive effect of a chemotherapeutic agent or irradiation, or to potentiate the effect of a chemotherapeutic agent.
摘要翻译：药物组合物及其使用方法。谷胱甘肽类似物的脂质制剂及其制造方法。它们用于刺激造血，保护造血细胞免受辐射或化疗引起的损伤，或增强细胞因子对造血祖细胞的集落形成的一种或组合的刺激作用，保护受试者免受化学治疗剂或辐射的破坏作用，或增强化学治疗剂的作用。

4. 发明申请

WO2011156045A2 TABLET FORMULATION OF EZATIOSTAT 审中-公开
标题翻译： EZATIOSTAT的片剂配方
公开(公告)号：WO2011156045A2
公开(公告)日：2011-12-15
申请号：PCT/US2011030376
申请日：2011-03-29
申请人： TELIK INC , LUM ROBERT T , PARENT STEPHAN D , QIAO CHUNSHENG , SCHOW STEVEN R
发明人： LUM ROBERT T , PARENT STEPHAN D , QIAO CHUNSHENG , SCHOW STEVEN R
IPC分类号： A61K9/20 , A61K38/06 , C07K5/02
CPC分类号： C07K5/0215 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K31/165 , A61K31/216
摘要： Disclosed herein are tablets comprising ezatiostat hydrochloride wherein the ezatiostat hydrochloride comprises from about 75 to about 82 percent by weight of the tablet.
摘要翻译：本文公开了包含盐酸西替伐他汀的片剂，其中盐酸替扎他昔坦包含片剂的约75-约82重量％。

5. 发明申请

WO0071506A9 NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS 审中-公开
标题翻译：作为葡萄糖摄取增强剂的海绵脲
公开(公告)号：WO0071506A9
公开(公告)日：2001-09-20
申请号：PCT/US0014644
申请日：2000-05-25
申请人： TELIK INC
发明人： SPEVAK WAYNE , LUM ROBERT T , SHI SONGYUAN , MANCHEM PRASAD , KOZLOWSKI MICHAEL R , SCHOW STEVEN R
IPC分类号： C07D233/32 , A61K31/18 , A61K31/216 , A61K31/255 , A61K31/41 , A61K31/4166 , A61K31/4406 , A61K31/445 , A61K31/4965 , A61K31/505 , A61K31/662 , A61P3/10 , A61P43/00 , C07B59/00 , C07C273/00 , C07C275/42 , C07C303/22 , C07C303/30 , C07C303/38 , C07C309/51 , C07C309/58 , C07C309/76 , C07C309/88 , C07C311/21 , C07C311/47 , C07C335/16 , C07C335/18 , C07C335/32 , C07D211/60 , C07D211/96 , C07D213/76 , C07D233/36 , C07D239/42 , C07D241/20 , C07D257/04 , C07F9/40 , A61K31/395 , C07D335/18
CPC分类号： C07D257/04 , C07C309/51 , C07C311/47 , C07C335/16 , C07C335/18 , C07C335/32 , C07D211/96 , C07D213/76 , C07D233/36 , C07D239/42 , C07D241/20 , C07F9/4021
摘要： Compounds of formula (I), wherein R and R are substituents on the A rings and are, independently, -SO2NR 2, -C(O)NR 2, -NR SO2R , -NR C(O)R , -SO2OR , -C(O)OR , -OSO2R , or -OC(O)R , R and R are, independently, hydrogen or lower alkyl, or R and R together are -(CH2)2-, -(CH2)3-, or -(CH2)4-, or R or R may be an electron pair, R and R are, independently, hydrogen, alkyl, substituted alkyl, cyano, halo, nitro, -SR , -C(O)R , -SO2OR , -OSO2R , -SO2NR 2, -NR SO2R , -OC(O)R , -C(O)OR , -C(O)NR 2, -NR C(O)R , -OR , or -NR 2, each R and R is, independently, hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aryl(lower)alkyl, substituted aryl(lower)alkyl, heteroaryl(lower)alkyl, substituted heteroaryl(lower)alkyl, heterocyclyl, substituted heterocyclyl, heteroaryl, or substituted heteroaryl, each Y is, independently, a non-interfering substituent which is not linked to the naphthalene ring via an azo or amide linkage, each x is independently, 0, 1 or 2, and the linker connects a carbon designated as c to a carbon designated as d, or a pharmaceutically acceptable salt thereof, as a single stereoisomer or mixture of stereoisomers, are useful for treating conditions associated with hyperglycemia, especially Type II diabetes, with dinaphthylureas. These compounds are useful in stimulating the kinase activity of the insulin receptor, activating the insulin receptor, and stimulating the uptake of glucose. Pharmaceutical compositions comprising the antidiabetic compounds are also disclosed.
摘要翻译：式（I）化合物，其中R 1和R 2是A环上的取代基，并且独立地是-SO 2 NR 7，-C（O）NR 7，-NR 7 SO 2 R 7，-NR 7 C（O）R 7，-SO 2 OR 7，-C（O）OR 7，-OSO 2 R 7或-OC（O） R 3和R 4独立地是氢或低级烷基，或者R 3和R 4一起是 - （CH 2）2 - ， - （CH 2）3 - 或 - （ CH 2）4 - 或R 3或R 4可以是电子对，R 5和R 6独立地是氢，烷基，取代的烷基，氰基，卤素，硝基，-SR 8，-C（O）R 8，-SO 2 OR 8，-OSO 2 R 8，-SO 2 NR 8，-NR 8 SO 2 R 8，-OC（O）R 8 ，-C（O）OR 8，-C（O）NR 8，-NR 8 C（O）R 8，-OR 8或-NR 8 2 ，每个R 7和R 8独立地是氢，烷基，取代的烷基，芳基，取代的芳基，芳基（低级）烷基，取代的芳基（低级）烷基，杂芳基（低级）烷基，取代的杂芳基）烷基，杂环基，取代的杂环基，杂芳基或取代的杂芳基，每个Y独立地是通过偶氮偶联不与萘环连接的非干扰性取代基 r酰胺键，每个x独立地为0,1或2，并且连接体将指定为c的碳连接到指定为d的碳或其药学上可接受的盐作为单一立体异构体或立体异构体的混合物可用于治疗与高血糖症相关的病症，特别是II型糖尿病，与二萘基脲。这些化合物可用于刺激胰岛素受体的激酶活性，激活胰岛素受体，并刺激葡萄糖摄取。还公开了包含抗糖尿病化合物的药物组合物。

6. 发明申请

WO0071506A2 NOVEL NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS 审中-公开
标题翻译：新的海参作为葡萄糖摄取增强剂
公开(公告)号：WO0071506A2
公开(公告)日：2000-11-30
申请号：PCT/US0014644
申请日：2000-05-25
申请人： TELIK INC
发明人： SPEVAK WAYNE , LUM ROBERT T , SHI SONGYUAN , MANCHEM PRASAD , KOZLOWSKI MICHAEL R , SCHOW STEVEN R
IPC分类号： C07D233/32 , A61K31/18 , A61K31/216 , A61K31/255 , A61K31/41 , A61K31/4166 , A61K31/4406 , A61K31/445 , A61K31/4965 , A61K31/505 , A61K31/662 , A61P3/10 , A61P43/00 , C07B59/00 , C07C273/00 , C07C275/42 , C07C303/22 , C07C303/30 , C07C303/38 , C07C309/51 , C07C309/58 , C07C309/76 , C07C309/88 , C07C311/21 , C07C311/47 , C07C335/16 , C07C335/18 , C07C335/32 , C07D211/60 , C07D211/96 , C07D213/76 , C07D233/36 , C07D239/42 , C07D241/20 , C07D257/04 , C07F9/40 , C07C309/00
CPC分类号： C07D257/04 , C07C309/51 , C07C311/47 , C07C335/16 , C07C335/18 , C07C335/32 , C07D211/96 , C07D213/76 , C07D233/36 , C07D239/42 , C07D241/20 , C07F9/4021
摘要： Compounds of formula (I), wherein R and R are substituents on the A rings and are, independently, -SO2NR 2, -C(O)NR 2, -NR SO2R , -NR C(O)R , -SO2OR , -C(O)OR , -OSO2R , or -OC(O)R , R and R are, independently, hydrogen or lower alkyl, or R and R together are -(CH2)2-, -(CH2)3-, or -(CH2)4-, or R or R may be an electron pair, R and R are, independently, hydrogen, alkyl, substituted alkyl, cyano, halo, nitro, -SR , -C(O)R , -SO2OR , -OSO2R , -SO2NR 2, -NR SO2R , -OC(O)R , -C(O)OR , -C(O)NR 2, -NR C(O)R , -OR , or -NR 2, each R and R is, independently, hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aryl(lower)alkyl, substituted aryl(lower)alkyl, heteroaryl(lower)alkyl, substituted heteroaryl(lower)alkyl, heterocyclyl, substituted heterocyclyl, heteroaryl, or substituted heteroaryl, each Y is, independently, a non-interfering substituent which is not linked to the naphthalene ring via an azo or amide linkage, each x is independently, 0, 1 or 2, and the linker connects a carbon designated as c to a carbon designated as d, and is (a), where K is O, S, or NR*, and R* is H, cyano, or lower alkyl; or (b) or (c), where R* is H or lower alkyl; or (d) or (e), where R* is H, cyano, or lower alkyl; or (f), where R* is cyano or lower alkyl; and, where, if R and R are both -SO2OH, then: i) no Y is -SO2OH; ii) neither R nor R is -SO2OR or -OSO2R ; and iii) R and R are not both selected from the group consisting of hydroxy and hydrogen unless at least one (Y)x is (Y')x' wherein x' is 1 or 2 and Y' is a halo, or a pharmaceutically acceptable salt thereof, as a single stereoisomer or mixture of stereoisomers, are useful for treating conditions associated with hyperglycemia, especially Type II diabetes, with dinaphthylureas. These compounds are useful in stimulating the kinase activity of the insulin receptor, activating the insulin receptor, and stimulating the uptake of glucose. Pharmaceutical compositions comprising the antidiabetic compounds are also disclosed.
摘要翻译：式（I）化合物，其中R 1和R 2是A环上的取代基，并且独立地是-SO 2 NR 7，-C（O）NR 7，-NR 7 SO 2 R 7，-NR 7 C（O）R 7，-SO 2 OR 7，-C（O）OR 7，-OSO 2 R 7或-OC（O） R 3和R 4独立地是氢或低级烷基，或者R 3和R 4一起是 - （CH 2）2 - ， - （CH 2）3 - 或 - （ CH 2）4 - 或R 3或R 4可以是电子对，R 5和R 6独立地是氢，烷基，取代的烷基，氰基，卤素，硝基，-SR 8，-C（O）R 8，-SO 2 OR 8，-OSO 2 R 8，-SO 2 NR 8，-NR 8 SO 2 R 8，-OC（O）R 8 ，-C（O）OR 8，-C（O）NR 8，-NR 8 C（O）R 8，-OR 8或-NR 8 2 ，每个R 7和R 8独立地是氢，烷基，取代的烷基，芳基，取代的芳基，芳基（低级）烷基，取代的芳基（低级）烷基，杂芳基（低级）烷基，取代的杂芳基）烷基，杂环基，取代的杂环基，杂芳基或取代的杂芳基，每个Y独立地是通过偶氮偶联不与萘环连接的非干扰性取代基 r酰胺键，每个x独立地为0,1或2，并且连接体将指定为c的碳连接到指定为d的碳上，并且是（a），其中K是O，S或NR *，R *是H，氰基或低级烷基; 或（b）或（c），其中R *为H或低级烷基; 或（d）或（e），其中R *是H，氰基或低级烷基; 或（f），其中R *是氰基或低级烷基; 并且其中，如果R 1和R 2均为-SO 2 OH，则：i）不是Y是-SO 2 OH; ii）R 5和R 6都不是-SO 2 OR 8或-OSO 2 R 8; 和iii）R 5和R 6不均选自羟基和氢，除非至少一个（Y）x为（Y'）x'，其中x'为1或2，Y'为作为单一立体异构体或立体异构体混合物的卤素或其药学上可接受的盐可用于治疗与高血糖症，特别是II型糖尿病相关的病症与二萘基脲。这些化合物可用于刺激胰岛素受体的激酶活性，激活胰岛素受体，并刺激葡萄糖摄取。还公开了包含抗糖尿病化合物的药物组合物。

7. 发明专利

AT455779T 未知
公开(公告)号：AT455779T
公开(公告)日：2010-02-15
申请号：AT05020467
申请日：2001-05-02
申请人： TELIK INC
发明人： HERR JASON R , MENG FANYING , LUM ROBERT T , KOZLOWSKI MICHAEL R , SCHOW STEVEN R , ZHICHKIN PAVEL
IPC分类号： A61K45/00 , C07F9/24 , A61K31/664 , A61P31/10 , A61P33/00 , A61P35/00 , A61P35/04 , A61P43/00
摘要： The invention relates to novel bis-(N,N'-bis-(2-haloethyl)amino) phosphoramidates which are useful in the treatment of tumors and especially for the treatment of cancer, as well as to processes for their preparation.

8. 发明专利

FR2830531B1 未知
公开(公告)号：FR2830531B1
公开(公告)日：2006-09-22
申请号：FR0214025
申请日：2002-11-08
申请人： TELIK INC
发明人： SPEVAK WAYNE R , SHI SONGYUAN , MANCHEM PRASAD VVSV , KOZLOWSKI MICHAEL R , SCHOW STEVEN R , LUM ROBERT T , ROBINSON LOUISE , PARK JEONG WEON
IPC分类号： C07C309/52 , C07D215/40 , A61K31/167 , A61K31/18 , A61K31/185 , A61K31/192 , A61K31/198 , A61K31/341 , A61K31/343 , A61K31/4409 , A61K31/455 , A61K31/47 , A61K31/498 , A61P3/10 , A61P43/00 , C07C237/42 , C07C309/51 , C07C309/59 , C07C311/13 , C07C311/21 , C07C311/29 , C07C311/46 , C07D213/81 , C07D213/82 , C07D215/48 , C07D241/44 , C07D307/68 , C07D307/85
摘要： Methods for treating conditions associated with hyperglycemia, especially Type II diabetes, with novel naphthylsulfonic acids and related compounds. These compounds, as single stereoisomers or mixtures of stereoisomers, or their pharmaceutically acceptable salts, are useful in methods of stimulating the kinase activity of the insulin receptor, enhancing the activation of the insulin receptor by insulin, and stimulating the uptake of glucose into cells. A variety of antidiabetic compounds and pharmaceutical compositions comprising the antidiabetic compounds are also disclosed.

9. 发明专利

AU2001275081B2 Substituted stilbenes as glucose uptake enhancers 未知
公开(公告)号：AU2001275081B2
公开(公告)日：2005-07-21
申请号：AU2001275081
申请日：2001-06-01
申请人： TELIK INC
发明人： LUM ROBERT T , PARK JEONG WEONG , PATTERSON JOHN , SPEVAK WAYNE R
IPC分类号： C07D317/68 , A61K31/196 , A61K31/24 , A61K31/245 , A61K31/36 , A61K45/00 , A61P3/10 , C07C231/02 , C07C231/12 , C07C233/81 , C07C233/88 , C07C235/56 , C07C235/64 , C07C235/84 , C07C237/40 , C07C237/42 , C07C309/51 , C07C309/61 , C07D317/60 , A61K031/24 , A61K031/196
摘要： Compound of formula Iactivate the insulin receptor kinase. Pharmaceutical compositions comprising the compounds, and methods of treatment of hyperglycemia and other diseases involving imbalance of glucose levels, especially for the treatment of type II diabetes, by administering these compounds to mammalian hosts, and processes for their preparation, are also described.

10. 发明专利

AT280148T 未知
公开(公告)号：AT280148T
公开(公告)日：2004-11-15
申请号：AT01941753
申请日：2001-06-01
申请人： TELIK INC
发明人： PATTERSON JOHN , PARK JEONG WEONG , LUM ROBERT T , SPEVAK WAYNE R
IPC分类号： C07D317/68 , A61K31/196 , A61K31/24 , A61K31/245 , A61K31/36 , A61K45/00 , A61P3/10 , C07C231/02 , C07C231/12 , C07C233/81 , C07C233/88 , C07C235/56 , C07C235/64 , C07C235/84 , C07C237/40 , C07C237/42 , C07C309/51 , C07C309/61 , C07D317/60
摘要： Compound of formula Iactivate the insulin receptor kinase. Pharmaceutical compositions comprising the compounds, and methods of treatment of hyperglycemia and other diseases involving imbalance of glucose levels, especially for the treatment of type II diabetes, by administering these compounds to mammalian hosts, and processes for their preparation, are also described.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式